Validation experiments included Western blotting, co-immunoprecipitation, and pharmacological inhibition using OGX-427 and mTOR inhibitors (Everolimus, Sapanisertib) in prostate cancer cell lines, patient-derived organoids (PDOs), and xenograft models. Here, MTOR is linked to prostate carcinoma.